Cancers: What to Know About the Significant Advances at the American ASCO Congress – La Nouvelle Tribune

The annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago in early June 2026 unveiled a promising new treatment for pancreatic cancer. The drug daraxonrasib targets the KRAS mutation and doubled the life expectancy of patients in clinical trials. Each year, 16,000 new cases are diagnosed in France with a fatality rate of 80 to 90%. Researchers remain cautious but consider this the most significant advance in decades.